Amanote Research
Register
Sign In
Design and Synthesis of Novel Isoquinoline-3-Nitriles as Orally Bioavailable Kv1.5 Antagonists for the Treatment of Atrial Fibrillation
doi 10.1021/jm060927v.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
Novel, Orally Bioavailable G-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists
Potent and Orally Bioavailable 8-Bicyclo[2.2.2]octylxanthines as Adenosine A1 Receptor Antagonists
Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B1 Receptor Antagonists
Fragment-Based Drug Design and Identification of HJC0123 , a Novel Orally Bioavailable STAT3 Inhibitor for Cancer Therapy
European Journal of Medicinal Chemistry
Medicine
Organic Chemistry
Drug Discovery
Pharmacology
Dronedarone for the Treatment of Atrial Fibrillation and Atrial Flutter
Health Technology Assessment
Medicine
Health Policy
Design and Synthesis of Piperazinylpyridine Derivatives as Novel 5-Ht1a Agonists/5-Ht3 Antagonists for the Treatment of Irritable Bowel Syndrome (IBS)
Chemical and Pharmaceutical Bulletin
Medicine
Drug Discovery
Chemistry
Cardiac Radiosurgery for the Treatment of Atrial Fibrillation
World Journal of Cardiovascular Diseases
Design, Synthesis, and Structure-Activity Relationships of Thieno[2, 3-B]pyridin-4-One Derivatives as a Novel Class of Potent, Orally Active, Non-Peptide Luteinizing Hormone-Releasing Hormone Receptor Antagonists
The Surgical Treatment of Atrial Fibrillation
Surgical Clinics of North America
Surgery
